No Data
No Data
We Think That There Are Issues Underlying Gan & Lee Pharmaceuticals' (SHSE:603087) Earnings
Gan & Lee Pharmaceuticals.'s (SHSE:603087) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details. SHSE:603
Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2)
Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2) collection accelerated domestic replacement, and the company achieved rapid release of products; 3) renewals accelerated the pace of replacing second-generation insulin, further expanding the company's procurement base; 4) increasing investment in R&D and continuing to strengthen the sugar reduction product line; 5) speeding up the pace of going global and steadily advancing internationalization. (Mainichi Keizai Shimbun)
Ganli Pharmaceutical (603087): High-speed batch procurement of core products won the bid for the entire line
Guide to this report: The company's core products are being released at a high speed, and operational efficiency has improved markedly. The price increase for the entire line of collected products won the bid, which is expected to increase profits. Multiple potential catalysts, strong development momentum. Maintain an “Overweight” rating. Investment highlights: Performance is in line with expectations
Earnings Miss: Gan & Lee Pharmaceuticals. Missed EPS By 30% And Analysts Are Revising Their Forecasts
As you might know, Gan & Lee Pharmaceuticals. (SHSE:603087) last week released its latest quarterly, and things did not turn out so great for shareholders. Unfortunately, Gan & Lee Pharmaceutical
Ganli Pharmaceutical (603087.SH) reported 2023 results, with net profit of 340 million yuan, turning a year-on-year loss into a profit
Ganli Pharmaceutical (603087.SH) released its 2023 annual report, achieving revenue of 2,608 billion yuan, an increase of 52.31% over the previous year. Achieved net profit of 340 million yuan attributable to shareholders of listed companies, turning a year-on-year loss into a profit. Achieved net profit of 297 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, turning losses into profits over the previous year. It is proposed to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders.
Express News | Ganli Pharmaceutical: Net profit increased 95.04% year-on-year in the first quarter of 2024
No Data